Melanotan II

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of α-melanocyte-stimulating hormone (α-MSH) incorporating key structural modifications: replacement of methionine in the HFRW pharmacophore with norleucine (Nle), substitution of L-phenylalanine with D-phenylalanine (D-Phe) for improved melanocortin receptor affinity, and formation of an N-terminally acetylated, C-terminally amidated lactam-cyclized backbone connecting the Asp and Lys side chains. These structural features produce a peptide with broad melanocortin receptor agonism (MC1R–MC5R) and markedly enhanced potency and proteolytic resistance compared to linear α-MSH. In research settings, MT-II is used as a pharmacological tool to activate the melanocortin system broadly, with binding affinities in the low nanomolar range for all five MCR subtypes, enabling investigation of pigmentation, sexual arousal, appetite suppression, and autonomic regulation. Research employing Melanotan II in rodent models has extensively characterized its central actions on energy homeostasis and reproductive behavior. Intracerebroventricular and systemic MT-II administration in rats and mice produces dose-dependent reductions in food intake and body weight through hypothalamic MC4R activation in the paraventricular and dorsomedial nuclei, coupled with MC3R-mediated modulation of mesolimbic reward circuits. Sexual behavior studies using MT-II have defined the role of MC4R in the medial preoptic area (MPOA) and ventromedial hypothalamus (VMH) in mediating penile erection and lordosis behavior, respectively, establishing melanocortin signaling as a central regulator of copulatory function via dopaminergic and oxytocinergic intermediaries. At the peripheral level, MT-II research has characterized MC1R-dependent melanogenesis in melanocyte cultures and skin explant models, demonstrating stimulation of tyrosinase, TYRP-1, and TYRP-2 expression and eumelanin biosynthesis via cAMP-CREB-MITF transcriptional cascades. Studies in MC5R-expressing exocrine gland models have examined MT-II's effects on sebum composition and lacrimal secretion, while MC3R pharmacology has been explored in adipocyte metabolism, inflammation, and sympathetic outflow studies. The broad receptor engagement of MT-II makes it a versatile reference agonist in comparative pharmacology assays for melanocortin receptor subtype selectivity profiling.